Preclinical and clinical pharmacology of efegatran (LY294468): A novel antithrombin for the treatment of acute coronary syndromes

Clinical and Applied Thrombosis/Hemostasis

Volumn 2, Issue 4, 1996, Pages 258-267

  Jackson, Charles V ^a   Satterwhite, Julie ^a   Roberts, Eiry ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Efegatran; Myocardial infarction; Thrombin inhibitor; Thrombosis; Unstable angina

Indexed keywords

EID: 0003308863     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969600200406     Document Type: Article

References (30)

1. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;65:897.
2. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800.
3. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319: 1105.
4. Sherry S, Marder VJ. Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy. J Am Coll Cardiol 1992;19:678.
5. Théroux P. Antiplatelet and antithrombotic therapy in unstable angina. Am J Cardiol 1991;68:92B.
6. Roux S, Christeller S, Lüdin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992;19:671.
7. Kaiser B. Anticoagulant and antithrombotic actions of recombinant hirudin. Thromb Haemost 1991;17:130.
8. Heras M, Chesebro JH, Webster MWI, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. Circulation 1990;82:1476.
9. Sitko GR, Ramjit DR, Stabilito II, et al. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with selective factor Xa inhibitor, tick anticoagulant peptide: comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992;85:805.
10. Becker RC, Cannon CP. Hirudin: its biology and clinical use. J Thromb Thrombolysis 1994;1:7.
11. Topol EJ. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631.
12. Antman ET. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90: 1624.
13. Neuhaus K-L, Essen RV, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT III) study. Circulation 1994;90:1638.
14. Strony J, Bittl JA, Deutsch E, et al. Hirulog™ vs. heparin during percutaneous transluminal coronary angioplasty in patients with post-infarction angina: results of the myocardial infarction arm of the hirulog angioplasty trial [Abstract]. J Am Coll Cardiol 1995;25:357A.
15. Simoons ML, van Mittenburg A, Scheffer MG, et al. Anticoagulant properties of efegatran, a direct thrombin inhibitor in patients with unstable angina. Eur Heart J 1994;15:120.
16. Jackson CV, Crowe VG, Frank JD, et al. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 1992;261:546.
17. Mielke CH. International committee communications: measurement of the bleeding time. Thromb Haemost 1984;52: 210.
18. Bajusz S, Szell E, Badgy D, et al. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem 1990;33:1729.
19. 4. Thromb Haemost 1992;67:325.
20. Smith GF, Shuman RT, Craft TJ, et al. A family of arginal thrombin inhibitors related to efegatran. Thromb Haemost 1996;22:173-83.
21. Stubbs MT, Bodde W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res 1993;69:1.
22. Fenton JW II, Ni F, Witting JI, et al. The rational design of thrombin-directed antithrombotics. In: Claeson G, ed. The design of synthetic thrombin inhibitors. New York: Plenum, 1993:1.
23. Jackson CV, Wilson HC, Crowe VG, et al. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis. J Cardiovasc Pharmacol 1993;21:587.
24. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993.
25. Lee L, and the TIMI 6 Investigators. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 1995;75:7.
26. Théroux P, Pérez-Villa F, Waters D, et al. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91:2132.
27. Prager NA, Torr-Brown SR, Sobel BE, et al. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J Am Coll Cardiol 1993;22:296.
28. Yasuda T, Gold HK, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990;16:714.
29. Rote W, Mu D-X, Bates E, et al. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin. J Cardiovasc Pharmacol 1994;23:203.
30. Zoldhelyi P, Webster MWI, Fuster V, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease: safety, half-life, and effect on coagulation parameters. Circulation 1993;88:2015.